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AbstrAct
O-GlcNAcylation is a reversible post-translational modification. O-GlcNAc addition 
and removal is catalyzed by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), 
respectively. More recent evidence indicates that regulation of O-GlcNAcylation is 
important for inflammatory diseases and tumorigenesis. In this study, we revealed 
that O-GlcNAcylation was increased in the colonic tissues of dextran sodium sulfate 
(DSS)-induced colitis and azoxymethane (AOM)/DSS-induced colitis-associated 
cancer (CAC) animal models. Moreover, the O-GlcNAcylation level was elevated in 
human CAC tissues compared with matched normal counterparts. To investigate the 
functional role of O-GlcNAcylation in colitis, we used OGA heterozygote mice, which 
have an increased level of O-GlcNAcylation. OGA+/- mice have higher susceptibility 
to DSS-induced colitis than OGA+/+ mice. OGA +/- mice exhibited a higher incidence of 
colon tumors than OGA+/+ mice. In molecular studies, elevated O-GlcNAc levels were 
shown to enhance the activation of NF-κB signaling through increasing the binding of 
RelA/p65 to its target promoters. We also found that Thr-322 and Thr352 in the p65-
O-GlcNAcylation sites are critical for p65 promoter binding. These results suggest that 
the elevated O-GlcNAcylation level in colonic tissues contributes to the development 
of colitis and CAC by disrupting regulation of NF-κB-dependent transcriptional activity.
IntroductIon
The addition of O-linked β-N-acetylglucosamine 
(O-GlcNAc) monosaccharides to Ser and Thr residues of 
nuclear, mitochondrial and cytoplasmic proteins is termed 
O-GlcNAcylation. The addition and removal of O-GlcNAc 
on target proteins is catalyzed by O-GlcNAc transferase 
(OGT) and O-GlcNAcase (OGA), respectively [1]. The 
O-GlcNAc cycling enzymes are expressed ubiquitously 
and are critical for development in vertebrates . Abnormal 
amounts of O-GlcNAcylation contribute to the etiology 
of chronic aging diseases, including cardiovascular 
disease, type 2 diabetes and Alzheimer’s disease [2, 
3]. O-GlcNAc-modified proteins play diverse roles 
in transcriptional regulation, the cell cycle, signaling, 
stress, and differentiation [1]. Because the cellular 
roles of O-GlcNAc-modified proteins are perturbed 
during tumorigenesis, aberrant O-GlcNAcylation was 
suggested to be closely linked to tumorigenesis [4]. 
OGT was reported to regulate transcriptional machinery 
by modifying the many transcription factors involved in 
cancer-relevant processes [4]. Notably, O-GlcNAc levels 
Oncotarget12530www.impactjournals.com/oncotarget
are significantly elevated in various cancer types, including 
those of the breast [5], prostate [6], colon [7], lung [8], 
pancreas [9] and chronic lymphocytic leukemia [10]. In 
vivo xenograft of breast [11], prostate [6] and pancreatic 
cancers [9] showed a critical role for O-GlcNAcylation 
in tumorigenesis or metastasis. However, the effect of 
O-GlcNAcylation in colorectal cancer (CRC) has not been 
demonstrated in vivo.
CRC is one of the most common malignancies, for 
which inflammation is an established risk factor [12]. 
Ulcerative colitis (UC), a common form of inflammatory 
bowel disease (IBD), is associated with an increased risk 
of CRC [13]. The NF-κB signaling pathway plays a pivotal 
role in the development and maintenance of intestinal 
inflammation [14]. Activation of NF-κB signaling was 
detected in mucosal IBD cells and colorectal carcinoma 
patients [15, 16]. Previous studies have suggested that 
NF-κB signaling plays a key role in linking intestinal 
inflammation with CRC development [17]. A number of 
genetic mouse models have demonstrated that aberrant 
NF-κB signaling in mucosal immune cells or intestinal 
epithelial cells leads to severe intestinal inflammation and 
tumors [18-20]. Many reports have shown that NF-κB 
signaling is affected by O-GlcNAcylation. However, no 
clear pattern in NF-κB activity in the presence of increased 
O-GlcNAc levels has been reported. O-GlcNAcylation of 
RelA/p65, a subunit of NF-κB, is critical for activation 
of NF-κB signaling in mesangial cells and T- and 
B-lymphocytes [21, 22]. p65 is O-GlcNAcylated on 
Thr-352, which is required for transcriptional activity 
under hyperglycemic conditions [23]. Mutation of two 
p65 O-GlcNAc sites (T322A and T352A) attenuated 
the growth of pancreatic ductal adenocarcinoma [9]. 
Furthermore, transforming growth factor-β-activated 
kinase1-binding protein (TAB1), an upstream signaling 
molecule of NF-κB, is O-GlcNAcylated and necessary 
for activation of NF-κB signaling during the innate 
immune response [24]. In contrast, several reports have 
suggested that elevated O-GlcNAcylation attenuates 
NF-κB signaling activation in rat aortic smooth muscle 
cells and primary cultured cardiomyocytes [25, 26]. 
Despite the increasing number of reports of a possible 
link between O-GlcNAcylation and inflammation, the 
pathogenetic role of O-GlcNAcylation in IBD and CRC, 
particularly when associated with chronic inflammation, 
has yet to be investigated. In this study we used OGA+/- 
mice with constitutively elevated colonic O-GlcNAc 
levels as an experimental model to investigate the role of 
O-GlcNAcylation in intestinal inflammation and colitis-
associated cancer. Our results showed that elevated 
O-GlcNAcylation significantly enhanced colitis and CAC 
in the colon by modulating p65 DNA-binding activity. 
results
elevation of o-GlcnAcylation in colitis
Although studies have suggested an association 
between O-GlcNAcylation and inflammation [24, 
25], the involvement of O-GlcNAcylation in IBD has 
not been investigated. First, we examined whether 
O-GlcNAcylation is altered in colitis. Wild-type (WT) 
mice were treated with 2% dextran sulfate sodium (DSS) 
in drinking water for 7 days to induce colitis, and then 
provided with normal water. Immunoblotting revealed that 
global O-GlcNAcylation and O-GlcNAc cycling enzymes 
were elevated in colonic tissues during DSS-induced 
colitis (Figure 1A and 1B). OGT expression was consistent 
with that of OGA during DSS treatment. Apparently, 
increased OGT expression elevates O-GlcNAcylation, 
causing an increase in OGA expression to compensate 
for the increased O-GlcNAcylation. Consistent with 
previous reports, Iκb and STAT3 were phosphorylated 
during colitis, indicating development of inflammation 
[15, 27]. Interestingly, O-GlcNAcylation is increased 
during colitis, simultaneous with the activation of 
inflammatory signaling. We also confirmed increased 
O-GlcNAc levels in colonic tissue of DSS-treated 
mice using immunohistofluorescence (Figure 1C). To 
investigate whether UDP-GlcNAc, a donor substrate for 
O-GlcNACylation, is also elevated in DSS-treated colon 
tissues, we measured UDP-GlcNAc levels by HPLC 
analysis in colon tissues after loading control samples 
from colon tissues (Supplementary Figure 1). UDP-
GlcNAc levels are increased in DSS-treated colon tissues 
compared with control tissues (Figure 1D). This result 
indicates that hyper-O-GlcNAcylation is caused by both 
increased flux of the hexosamine pathway and increased 
OGT expression.
To determine whether DSS affects directly the 
O-GlcNAc level in colonic epithelial cells, Caco2 and 
CT26 cells were treated with 3% DSS. DSS treatment 
increased O-GlcNAcylation in colon epithelial cells 
(Figure 1E). Notably, high levels of O-GlcNAcase 
expression was detected in colonic epithelial cells 
(Supplementary Figure 2). This finding suggests that 
O-GlcNAc modification might affect DSS-induced colitis 
progression in intestinal epithelial cells. Furthermore, we 
also tested whether DSS activates the NF-κB signaling 
in colonic epithelial cells and MEFs. However, p65 
phosphorylation, IκBα phosphorylation, and IκBα 
degradation were not changed by DSS treatment 
(Supplementary Figure 3). These results suggest that 
O-GlcNAc cycling may play an important role in the 
pathogenesis of colitis. 
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Increased levels of o-GlcnAcylation in mouse and 
human cAc
Next, we investigated whether O-GlcNAcylation is 
also increased in inflammation-associated tumorigenesis. 
O-GlcNAc levels were assayed in AOM/DSS-induced 
mouse colon tumors. We observed increased levels of 
O-GlcNAcylation in AOM/DSS-treated mice. O-GlcNAc 
levels were elevated in CAC tissues with increased STAT3 
phosphorylation, a well-known marker of inflammation, in 
the AOM/DSS model. (Figure 2A and 2B). These results 
suggest that O-GlcNAcylation is closely correlated with 
CAC. To confirm the elevated O-GlcNAcylation in CAC, 
we used a matched pair of adenomas and uninvolved 
colonic mucosa from CAC patients. CAC samples show 
elevated levels of the O-GlcNAcylation and STAT3 
phosphorylation compared to uninvolved colonic mucosa 
(Figure 2C and 2D). The elevated O-GlcNAcylation 
in CAC tissues might be a consequence of chronic 
inflammation, as observed in colitis. We speculate 
that increased O-GlcNAcylation may contribute to the 
development of CAC.
oGA+/- mice exhibit increased susceptibility to 
acute and chronic dss-induced colitis
Emerging evidences suggest that O-GlcNAcylation 
regulates NF-κB signaling which is important for immune 
hemostasis and inflammation in the intestine. NF-κB 
signaling controls the expression of factors regulates 
Figure 1: o-GlcnAcylation levels during dss treatment. Wild-type mice were administered 2% DSS in drinking water for 
the indicated days. (A) Western blots of lysates from wild-type mice treated with DSS during a 9-day time course. Lysates for each time 
point were isolated from three separate mice. Two representative samples were loaded in each lane. (b) Densitometry was performed on 
immunoblots. The ratio of O-GlcNAc to β-actin was determined. Error bars represent the S.D. (n = 3) and (**) P < 0.005, (*) P < 0.05 
(Student’s t-test). (c) Immunofluorescence staining of the colon with O-GlcNAc mAb (RL2) in wild-type mice not treated or treated 
with DSS for 7 days (green, O-GlcNAc modified proteins; blue, nuclei). Bars =50 µm. (d) Measurement of Uridine diphosphate-N-
acetylglucosamine (UDP-GlcNAc; B) levels in control (n=3) and DSS-treated (n=6) colon tissues by HPLC analysis (left). Matched 
O-GlcNAcylation levels (Immunoblots with RL2 antibody) (right). Error bars represent ± SEM. (*) P < 0.05 (Student’s t-test). (e) Caco2 
and CT26 cells were treated with 3% DSS for up to 48 hours. O-GlcNAcylation levels were analyzed by Western blot analysis. 
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apoptosis and proliferation during intestinal inflammation 
[14]. Previous studies show that disruption of NF-κB 
signaling in epithelium aggravates colitis with severe 
weight loss, tissue damage, and increased proinflammatory 
factors in the colonic mucosa [28]. These reports and the 
above results promoted us to investigate the involvement 
of O-GlcNAcylation in DSS-induced colitis and colonic 
inflammation. We used OGA+/- mice that have constantly 
elevated O-GlcNAcylation (Supplementary Figure 4A). 
Homozygous knockout of OGA is lethal perinatally 
[29]. Colitis was induced in OGA+/+ and OGA+/- mice by 
administration of 2% DSS in drinking water for 7 days, 
followed by normal drinking water. During the DSS 
treatment period, OGA+/- mice exhibited more severe 
body weight loss, with an average weight loss of 8% 
in OGA+/+ versus 21% in OGA+/- mice (Figure 3A). The 
OGA+/- mice exhibited significantly higher mortality than 
OGA+/+ mice during the recovery phase (Supplementary 
Figure 4B). OGA+/- mice exhibited more severe colon 
shortening (Figure 3B). Histological analysis by H&E 
staining showed that colon tissue from DSS-treated 
OGA+/+ mice had moderate inflammation and ulceration. 
Figure 2: elevated o-GlcnAcylation in mouse and human cAc. (A) Western blot of lysates form wild-type mice not treated or 
treated with AOM/DSS for 12 weeks. (b) Densitometry was performed on immunoblots. The ratio of O-GlcNAc to β-actin was determined. 
Error bars represent the S.D. (n = 3), (*) P < 0.05 (Student’s t-test). (c) Western blot analysis of O-GlcNAcylation level in 3 matched pairs 
of uninvolved colonic mucosa (N) and colitis-associated cancer (C) tissues. (d) Densitometry was performed on immunoblots. The ratio of 
O-GlcNAc to GAPDH was determined. Error bars represent the S.D. (n = 3), (**) P < 0.005 (Student’s t-test).
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However, OGA+/- mice displayed severe damage with 
extensive infiltration of neutrophils and a complete loss 
of crypt architecture (Figure 3C). In addition, OGA+/- 
mice showed rectal bleeding than OGA+/+ littermates, 
with a higher clinical score (Figure 3D). The extent of 
neutrophil infiltration was measured by MPO activity 
assay (Figure 3E). OGA+/- mice exhibited higher MPO 
activity than OGA+/+ mice, indicating increased neutrophil 
infiltration. Thus, these results suggest that increased 
O-GlcNAcylation aggravates DSS-induced mucosal 
damage, as indicated by the greater susceptibility of OGA+/- 
mice to DSS treatment. A number of proinflammatory 
cytokines mediate intestinal inflammation. Therefore, 
we compared cytokine production in colon samples 
from OGA+/+ and OGA+/- mice before and after DSS 
treatment. As shown in Figure 3F, OGA+/- mice exhibited 
a marked increase in DSS-induced colonic production 
of proinflammatory cytokines (IL-1β and IL-6) and 
chemokines (CXCL1 and CCL2). Consistent with these 
results, activation of the inflammatory pathway including 
NF-κB and STAT3 signaling, in the colon of DSS-treated 
OGA+/- mice was greater than in OGA+/+ mice due to the 
elevated O-GlcNAc levels of OGA+/- mice (Figure 3G). 
We next investigated the roles of O-GlcNAcylation 
in the DSS-induced chronic colitis. The chronic colitis 
was induced 3 cycles of 3% DSS treatment for 5 days 
by 14 days of water. Consistent with the results of acute 
colitis, OGA+/- mice showed increased susceptibility to 
chronic colitis compared with OGA+/+ mice. OGA+/- mice 
exhibited increased body weight loss (Figure 3H) and 
Figure 3: OGA+/- mice exhibit increased susceptibility to acute dss-induced colitis and chronic colitis. Eight-week-old 
OGA+/+ and OGA+/- mice were treated with 2% DSS for 7 days and examined for clinical signs of colitis. (A) Weights of mice during 
the 7-day treatment period. n = 5 mice per group. (b) Photographs of representative colons and ceca from untreated and DSS-treated 
OGA+/+ and OGA+/- mice. Colon length, measured at day 7 after treatment. (c) H&E-stained distal colonic sections after 7 days of DSS 
treatment and histological scores. Bars=100 µm. (d) Clinical scores. (e) MPO activity as a measure of neutrophil infiltration. (F) Cytokines 
and chemokines measured by Luminex multiplex. n = 5 mice per group. Error bars represent ± SEM. (**) P < 0.005, (*) P < 0.05 
(Student’s t-test). (G) Colon tissue extracts from OGA+/+ and OGA+/- mice after 7 days of DSS treatment and after 3 days of recovery were 
immunoblotted with antibodies. (H) The mice were treat with 3 cycles of 3% DSS treatment followed by 14 days of water. The mice were 
analyzed on day 52. The mean changes in body weight of OGA+/+ and OGA+/- mice. n = 13 mice per group. (I) Histological scores (J) Colon 
length. n = 5 mice per group. Error bars represent ± SEM. (**) P < 0.005, (*) P < 0.05 (Student’s t-test). 
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decreased survival rate during chronic colitis progression 
(Supplementary Figure 5A). Severe colitis of OGA+/- 
mice were reflected by histopathological image analysis 
(Supplementary Figure 5B) with higher histological 
scores (Figure 3I) and colonic shortening compared to 
OGA+/+ mice (Figure 3J). Overall, these results indicate 
that increased O-GlcNAcylation aggravates intestinal 
inflammation in a mouse model of colitis.
Increased o-GlcnAcylation contributes to colitis-
associated colorectal cancer
To further characterize the effects of elevated 
O-GlcNAcylation on DSS-induced colitis, we examined 
whether increased O-GlcNAcylation promotes the 
development of CAC. OGA+/+ and OGA+/- mice were 
assessed using the AOM/DSS model of CAC. As expected, 
OGA+/- mice exhibited a higher mortality rate than OGA+/+ 
mice (Figure 4A). The early death of OGA+/- mice might 
be associated with greater susceptibility to DSS-induced 
colitis as observed in Figure 3 and Supplementary Figure 
4. Both OGA+/+ and OGA+/- mice developed tumors in the 
middle-to-distal portion of the colon (Figure 4B). OGA+/- 
mice developed a markedly greater number of tumors 
(Figure 4C). The average tumor size was also significantly 
greater in OGA+/- mice than OGA+/+ mice (Figure 4D). 
Histological examination consistently showed larger 
adenomas in colonic sections of OGA+/- mice compared 
with OGA+/+ mice (Figure 4E). These results reflect the 
result showing reduced survival rate of OGA+/+ mice. 
These results indicate that increased O-GlcNAcylation 
may accelerate tumor development. 
Increased o-GlcnAcylation enhances lPs-
induced activation of nF-κb signaling
Intestinal inflammation is caused by a dysregulated 
mucosal immune response to luminal bacteria. LPS 
and other bacterial products are recognized Toll-like 
receptors (TLRs), which lead to NF-κB signaling 
Figure 4: elevated o-GlcnAcylation contributes to colonic tumorigenesis in a mouse model of cAc. (A) OGA+/+ and 
OGA+/- mice littermate survival (18 of 21 OGA+/+ mice 9 of 20 OGA+/- mice). (b) Representative colons at the end of the CAC protocol. (c) 
Number of tumors per mouse and (d) tumor size. Size distribution of tumors is shown. (e) Representative H&E-stained colonic tumors at 
the end of the CAC protocol. Bars =200 µm.
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activation. TLR signaling is an important for luminal 
bacteria-induced intestinal inflammation [30, 31]. NF-κB 
signaling activation has been proposed as a link between 
inflammation and carcinogenesis by acting both in tumor 
and inflammatory cells to promote tumor development 
[32]. Notably, the key regulators of NF-κB signaling p65, 
IKKβ and TAK1, are O-glycosylated and regulated by this 
modification [23, 24, 33, 34]. 
To investigate how O-GlcNAcylation affects NF-
κB signaling in colonic epithelial cells, we examined the 
effect of increased O-GlcNAcylation on LPS-induced NF-
κB activation. We used Thiamet G, a potent and selective 
inhibitor of OGA (Supplementary Figure 6). As shown 
in Figure 5A, Thiamet G enhanced LPS-induced NF-κB 
reporter gene activation in CT26 colonic epithelial cells. 
Consistent with this result, the expression of NF-κB target 
genes (IL-1β and IL-6) induced by LPS stimulation was 
increased in Thiamet G-treated cells (Figure 5B and 5C). 
We also observed that OGA knockdown promotes LPS-
induced IL-1β and IL-6 mRNA production compared 
with control cells (Figure 5D and 5E). To further confirm 
the effect of increased O-GlcNAcylation, we used OGA-
/- mouse embryonic fibroblasts (MEFs). Similarly, the 
expression of NF-κB target genes was significantly 
increased in OGA-/- MEFs after LPS treatment compared 
with in wild-type (WT) MEFs (Figure 5F-5H). These 
results indicate that increased O-GlcNAcylation 
promotes LPS-induced activation of NF-κB signaling in 
colonic epithelial cells and MEFs. These data suggest 
that dysregulation of O-GlcNAcylation contributes to 
the development of colitis and CAC through enhancing 
activation of inflammatory pathway in intestinal epithelial 
cells.
NF-κB p65 subunit binding to promoter regions is 
regulated by o-GlcnAcylation 
In subsequent experiments, we investigated the 
effect of O-GlcNAcylation on the NF-κB signaling 
pathway by western blot. LPS treatment rapidly 
induced Iκb phosphorylation, Iκb degradation and p65 
phosphorylation in both control and OGA knockdown 
Caco2 cells (Supplementary Figure 7A). We observed 
the same results in OGA +/+ MEFs and OGA-/- MEFs 
(Supplementary Figure 7B). Since O-GlcNAcylation 
did not affect Iκb degradation and p65 phosphorylation, 
we next focused on p65 nuclear translocation. We found 
that elevated O-GlcNAcylation did not affect p65 nuclear 
translocation in OGA knockdown and Thiamet G-treated 
Figure 5: Increased O-GlcNAcylation enhances LPS induced-NF-κB signaling activation. (A) CT26 cells were transfected 
with an NF-κB promoter–reporter construct before LPS (100 ng/mL) and/or Thiamet G (1µM) treatment; luciferase activity was measured 
at 6 h. (b and c) SYBR Green-based RT-PCR analysis was carried out after treatment with LPS (100 ng/mL) and/or Thiamet G (1 µM) 
and expression levels of IL-1β and IL-6 were determined by comparison with GAPDH. (d and e) Control and OGA knockdown Caco2 
cell lines were stimulated with LPS and the mRNA levels of IL-1β and IL-6 were measured at 6h. (F-H) OGA+/+ and OGA-/- MEFs were 
stimulated by LPS (100 ng/ml) and the mRNA levels of TNF-α, IL-1β and IL-6 were measured at the indicated times post-stimulation. Error 
bars represent the S.D. (n = 3). (**) P < 0.005, (*) P < 0.05 (Student’s t-test 
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Caco2 cells (Supplementary Figure 7C) and found an 
identical result in OGA-/- MEFs and Thiamet G-treated 
OGA+/+ MEFs (Figure 6A). 
To determine whether elevated O-GlcNAcylation 
enhances DNA binding of p65, we performed a p65-
binding activity assay using nuclear extracts isolated from 
control Caco2 cells and Thiamet G-treated Caco2 cells. 
LPS significantly increased the binding activity of p65 in 
the control extract. LPS-induced p65 binding activity was 
significantly enhanced in extracts both Thiamet G-treated 
cells and OGA knockdown Caco2 cells (Figure 6B and 
6C). These results indicate that O-GlcNAcylation regulates 
p65 DNA-binding activity. Accordingly, we tested whether 
p65 was highly O-GlcNAcylated in DSS-treated colonic 
extracts. We detected elevated p65 O-GlcNAcylation in 
DSS-treated colon compared with control (Figure 6D). 
Next, we investigated whether p65 
O-GlcNAcylation affects promoter recruitment of p65 
using chromatin immunoprecipitation (ChIP) assay. A 
previous study reported that Thr-322 and Thr-352 of 
p65 are O-GlcNAcylated [23]. We determined whether 
Thr-322 or Thr-352 mutation disrupts p65 binding to 
target promoters. HEK293 cell were transfected with 
WT p65 or His-p65 mutants (T322A and T352A). The 
O-GlcNAc level of p65 mutants was reduced slightly 
in the presence of identical amounts of each expression 
plasmid (Supplementary Figure 8). WT p65 was recruited 
to IL-6, TNF-α and MCP-1 promoter elements. However, 
Figure 6: The O-GlcNAcylation site of p65 is important for binding of p65 to the promoter elements. (A) OGA+/+, OGA-/-, 
and Thiamet G-treated- OGA+/+ MEFs were stimulated with LPS. The nuclear extracts were prepared and subjected to Western blot analysis. 
(b) NF-κB p65 subunit DNA binding activity was analyzed with nuclear extracts isolated from control and Thiamet G pre-treated Caco2 or 
(c) control and OGA knockdown Caco2 cell lines. (d) Water-treated or DSS-treated colon homogenates were used for immunoprecipitation 
with a polyclonal p65 antibody and immunoblotted against O-GlcNAc. The levels of p65 expression and O-GlcNAcylation were detected 
in input homogenates. Recruitment of p65 on the (e) (i) IL-6, (ii) TNF-α, (iii) MCP1 promoter, and (iv) GAPDH (control) were measured 
by p65 ChIP assay in HEK-293 cells expressing p65 WT, p65T322A or p65T352A. (F) p65 KO MEFs were transfected with plasmids 
containing p65 WT, p65T322A, p65T352A, or empty vector. RT-PCRs were performed to detect the p65 target genes, IL-6 and TNF-α. The 
expression of these plasmids expressing WT or mutant p65 were determined by immunoblotting with anti p65, His, and β-actin antibodies 
(right). Error bars represent the S.D. (n = 3). (**) P < 0.005, (Student’s t-test).
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mutation of Thr-322 or 352 to alanine reduced p65 binding 
to target promoters (IL-6, TNF-α and MCP1; Figure 
6E). Consistent with these data, overexpression of p65 
O-GlcNAcylation mutants in p65 KO MEFs exhibited 
reduced mRNA expression of IL-6 and TNF-α (Figure 6F). 
These findings indicate that p65 O-GlcNAcylation on Thr-
322 and Thr-352 is required for transcriptional activation 
of p65 and suggest that elevated p65 O-GlcNAcylation 
promotes NF-κB signaling by modulating promoter 
recruitment of p65.
dIscussIon
Many studies have suggested that NF-κB signaling 
is a critical link between inflammation and carcinogenesis. 
Although the involvement of O-GlcNAcylation in NF-κB 
signaling has been suggested, the molecular mechanism 
and physiological roles have not been elucidated. In 
this study, we showed that O-GlcNAcylation is elevated 
in intestinal inflammation. Notably, O-GlcNAcylation 
levels were elevated in mouse and human CAC, 
suggesting that O-GlcNAcylation contributes to chronic 
inflammation and tumor development. We showed that 
increased O-GlcNAcylation enhances sensitivity to DSS-
induced colitis and promotes CAC by modulating NF-κB 
signaling. O-GlcNAcylation of p65 affects its binding 
to target promoters. These results suggest a role for 
O-GlcNAc cycling in the pathogenesis of inflammatory 
bowel diseases and colorectal cancer.
Previous studies showed that NF-κB signaling 
is regulated by O-GlcNAcylation differently. 
O-GlcNAcylation of the Iκ-B kinase subunit β at Ser733, 
an inactivating phosphorylation site, is required for 
catalytic activity in response to high-glucose conditions 
[33]. The NF-κB p65 subunit is O-GlcNAcylated at 
Thr-305, Thr-322 and Thr-352. Point mutation of these 
sites revealed that O-GlcNAc modification at Thr-352 
regulates p65 transcriptional activity [23]. In addition, 
Thr-305 is essential for p65 transcriptional activity by 
potentiating p300-mediated acetylation [35]. These studies 
demonstrated that O-GlcNAcylation of both IKK and NF-
κB p65 enhances the transcriptional activity of NF-κB 
signaling under hyperglycemic conditions. In contrast, 
other studies have reported that elevated O-GlcNAcylation 
suppressed NF-κB signaling. Glucosamine (GlcN), a 
major product of the hexosamine biosynthesis pathway, 
or PUGNAC (OGA inhibitor) treatment inhibits TNF-α–
induced NF-κB signaling in vascular smooth-muscle cells 
by blocking NF-κB p65 Ser 536 phosphorylation [25]. In 
rat trauma hemorrhage, increased O-GlcNAc modification 
in the heart, liver and kidney improved cardiac function 
and organ perfusion with reduced activation of NF-κB 
signaling [26, 36]. Although reported in many studies, 
the role of O-GlcNAcylation in NF-κB signaling is 
dependent on the experimental design and conditions 
used. In the present study, we showed that increased 
O-GlcNAcylation caused by OGA deletion or knockdown 
did not affect Iκb degradation or p65 phosphorylation 
and nuclear translocation (Supplementary Figure 7). 
However, elevated O-GlcNAcylation affected NF-κB p65 
transcriptional activity by modulating p65 DNA binding 
(Figure 6B). Regarding phosphorylation of Iκb, this in 
vitro result is inconsistent with the in vivo data shown 
in Figure 3G. We speculate that elevated p65 promoter-
binding activity eventually aggravate colonic inflammation 
in DSS-treated OGA+/- mice. Consequently, OGA+/- mice 
exhibited increased Iκb and STAT3 phosphorylation 
compared with WT mice during colitis. Our finding is 
supported by reports of involvement of many O-GlcNAc–
modified proteins in transcriptional regulation: c-myc [37], 
FoxO-1 [38], PGC-1α [39], and HCF-1 [40]. 
Recent studies have suggested that dysregulation 
of O-GlcNAcylation is associated with tumor growth 
and metastasis. Correlatively, aberrant O-GlcNAcylation 
and protein levels of O-GlcNAc cycling enzymes are 
observed in tumors. O-GlcNAcylation levels are elevated 
in breast, lung, chronic lymphocytic leukemia, and colon 
tumors [5, 8, 10]. Consistent with these reports, we found 
that O-GlcNAcylation was elevated in the colon tissues 
of CAC mice, and OGA+/- mice showed an increased 
incidence of colorectal tumors compared to control 
mice. Evidently, NF-κB signaling contributes to cancer 
development and progression. Colon cancer cell lines and 
human tumor samples show increased activity of NF-κB, 
which is a crucial mediator of inflammation-induced tumor 
growth and progression [41, 42]. Based on these results, 
we suggest that elevation of O-GlcNAcylation aggravates 
chronic inflammation by enhancing NF-κB signaling 
activation, which contributes to CAC development. 
In contrast, OGA+/- mice were protected from tumor 
development in Apcmin/+ model of sporadic CRC [43]. 
This finding suggests that increased O-GlcNAcylation 
suppresses colorectal tumorigenesis. This observation 
indicates that O-GlcNAcylation differentially affects 
sporadic and inflammatory-driven tumorigenesis. We 
suggest that colitis-associated cancer which is different 
state of inflammation compared with sporadic cancer 
requires hyper-O-GlcNAyclation for enhancing NF-κB 
signaling in tumor growth and progression. Previous 
studies also suggest that the opposite effects on colorectal 
tumorigenesis in different types of colorectal cancer 
models is responsible for involvement of different 
signaling pathway [44, 45]. 
In addition to O-GlcNAcylation modulating NF-κB 
signaling, the effects of the many transcriptional mediators 
that are O-GlcNAcylated in colorectal tumorigenesis 
cannot be disregarded. Dysregulation of O-GlcNAcylation 
alters the activity of transcriptional mediators that 
contribute to tumor growth and metastasis [4, 46]. 
Consistent with these reports, reduced O-GlcNAcylation 
of FoxM1, an oncogenic transcription factor, via OGT 
knockdown in breast cancer cells leads to inhibition of 
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tumor growth both in vitro and in vivo [11]. Furthermore, 
phosphofructokinase 1 (PFK1) is O-GlcNAcylated. 
Inhibition of PFK1 O-GlcNAcylation blocks tumor 
growth in vivo [47]. Additionally, a proteomic study newly 
identified aberrant O-GlcNAcylated proteins involved in 
the stress response, biosynthesis, RNA metabolism, gene 
expression, cytoskeleton, and primary breast malignant 
tumors [48].
In summary, we demonstrated the role of 
O-GlcNAcylation in colitis and CAC using OGA+/- 
mice. Our results indicate that O-GlcNAc cycling is 
critical for regulation of NF-κB signaling in colitis 
and CAC. Therefore, we propose that dysregulation of 
O-GlcNAcylation is involved in diverse inflammatory 
diseases, and thus pharmacological modulation of 
O-GlcNAc cycling enzymes could be a novel therapeutic 
strategy for such conditions.
MAterIAls And MetHods
Mice
OGA+/- mice (C57BL/SV129) were generated as 
described previously [29]. OGA+/- mice were backcrossed 
with C57BL/6J wild-type mice. Mouse strains were bred 
and housed in the Animal Research Facility at POSTECH 
and UNIST.
Human patient samples
The biospecimens for this study were provided by 
the Pusan National University Hospital, a member of 
the National Biobank of Korea, which is supported by 
the Ministry of Health and Welfare. All samples derived 
from the National Biobank of Korea were obtained 
with informed consent under institutional review board-
approved protocols. All patients were included based 
on clinical, endoscopical, and pathological proven by 
gastroenterologists. Four tissue specimens were obtained 
from patients with CAC. A part of the colon with the 
cancer and a small segment of normal colon were obtained 
from patients with CAC. 
colitis and cAc induction 
To induce colitis, 7–8-week-old sex-matched OGA+/+ 
and OGA+/- mice were provided with 2% DSS (molecular 
weight, 35,000–50,000; MP Biomedicals, Solon, OH) in 
drinking water ad libitum for 7 days. CAC was induced as 
described previously [49], with some modifications since 
C57Bl/6J mice show low susceptibility to AOM/DSS-
induced CAC [50]. Mice were intraperitoneally injected 
with AOM (10 mg/kg body weight) and maintained on 
a regular diet and water for 7 days (OGA+/+ and OGA+/- 
mice). Mice were then subjected to five cycles of DSS 
treatment, in which each cycle consisted of 1.5% DSS 
for 7 days (OGA+/+ and OGA+/- mice) followed by a 7-day 
recovery period with regular water. 
clinical activity score
Body weight loss, stool consistency and the presence 
of occult/gross blood were assessed daily for each mouse 
as described previously [51], with some modifications. 
Body weight change was scored as follows: 0, no change; 
1, 1–5% weight loss; 2, 5–10% weight loss; 3, 10–20% 
weight loss; 4, >20% weight loss. Stool character was 
scored as follows: 0, normal; 1, soft with well-formed 
pellets; 2, soft without pellets; 3, diarrhea. Occult blood 
was scored as follows: 0, no blood; 2, blood; 3, gross 
bleeding. These scores were added to generate a clinical 
activity score ranging from 0 to 10.
Myeloperoxidase (MPo) activity
MPO activity was determined using the EnzChek 
MPO Activity Assay Kit (Invitrogen) according to 
the manufacturer’s instructions. Briefly, the colon 
was homogenized in MPO assay buffer and the 
homogenate was centrifuged at 13000× g for 15 min 
at 4°C. Supernatants were used for assay. The protein 
concentrations in all tissue extracts were adjusted to 1 
mg/ml. The absorbance at 412 nm was measured using a 
spectrophotometer.
cytokine measurements
To assay cytokine levels in colon tissue, a part of the 
colon was homogenized mechanically in PBS containing 
0.1% Triton-X100 and a complete protease inhibitor 
mixture. Mouse cytokines and chemokines in colon 
homogenates were determined by Luminex assay (Bio-
Rad, Hercules, CA).
Measurement of udP-GlcnAc
UDP-GlcNAc levels were determined using by 
HPLC analysis of extracts of colon tissue samples as 
previously described [52]. Briefly, colon tissues are 
homogenized in 70% ice-cold ethanol. Then the lysates are 
further lysed on the ice using a handy sonic disruptor. The 
extract was centrifuged at 16,000 × g for 10 min at 4°C in 
order to remove insoluble material, and the supernatant 
was lyophilized. Purification of the extracted nucleotide 
sugars, and separation and quantification by ion pair 
reversed phase HPLC, have already been reported in detail 
previously [52].
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cell culture and generation of MeFs
The human (Caco-2) and mouse (CT26) colonic 
epithelial cell lines, and RAW264.7 cell lines were 
purchased from the American Type Culture Collection 
(ATCC); (Caco2, 2010), (CT26, 2010), and Cell lines 
were cultured in the recommended ATCC media. Cell 
line authentication was done by ATCC. Cells were daily 
checked by morphology and tested to be Mycoplasma 
free by PCR 1 weeks after recovery from frozen stocks in 
culture. These cell lines were routinely cultured at 37°C 
in 5% CO
2
. The cultures were maintained for no longer 
than 8 weeks after recovery from frozen stocks in culture. 
Primary MEFs were isolated from 12.5–14.5 dpc embryos 
from heterozygous mice breeding. After removal of the 
intestinal organs and head, embryos were washed with 
phosphate-buffered saline (PBS), minced and trypsinized. 
After centrifugation, the dissociated cells were plated in 
medium. The medium was composed of DMEM glutamax, 
10% FBS, Pen/Strep and 1% non-essential amino acids. 
Genotyping was done by both PCR and Western blot. 
Early passage (P<4) MEFs were used for all experiments. 
Western blotting
Tissue and cell lysates were prepared using standard 
procedures. Samples of 20–30 µg of protein were 
separated on an SDS-polyacrylamide gel and visualized. 
Western blotting antibodies used were anti-phospho-IκB-α 
(9246; Cell Signaling Technology), anti-IκB-α (4812; 
Transduction Laboratories), anti-Stat3 (Transduction 
Laboratories), anti-phospho-Stat3 (9131; Cell Signaling 
Technology), anti-phoshpo-p65 (3036; Cell Signaling 
Technology), anti-p65 (ab7970; Abcam), anti-Lamin B 
(6216; Santa Cruz Biotechnology Inc.), anti-O-GlcNAc 
(CTD110.6)(9875; Cell Signaling Technology), anti-O-
GlcNAc (RL2)(MA1-072; Thermo), and β-actin (691001; 
MP Biomedicals). Anti-OGA polyclonal antibodies had 
been previously generated and were used as previously 
described.[53] The peroxidase-labeled goat anti-rabbit IgG 
and the goat anti-mouse IgA, IgM, and IgG used as the 
secondary antibodies were obtained from Kirkegaard & 
Perry Laboratories (KPL, Gaithersburg).
NF-κB transcriptional activity assay
To assay NF-κB transcriptional activity, colonic 
epithelial cells were seeded (1×104/well) in a 24-well 
plate. After reaching 60% confluence, the cells were 
transiently transfected with 0.5 µg of NF-κB-luciferase 
promoter-reporter construct (pGL4.32 [luc2P/NF-κB 
-RE/Hygro]) and 0.1 µg of control reporter plasmid 
(pRL-TK), containing the Renilla reniformis luciferase 
gene downstream of the TK promoter. Transfections 
were carried out using Lipofectamine (Invitrogen) as a 
transfection reagent. Twenty-four hours after transfection, 
the cells were treated with LPS, washed with ice-cold PBS 
and harvested in reporter lysis buffer. Luciferase activity 
was measured using the Dual Luciferase Assay System. 
All experiments were performed in triplicate and relative 
luciferase activity was reported as the fold induction after 
normalization for transfection efficiency.
statistical analysis
Data are presented as means ± standard errors of the 
means (SEMs) or standard deviation (SD) as indicated in 
the figure legends. Comparisons between two groups were 
made by unpaired two-tailed Student’s t tests. P values of 
<0.05 were considered statistically significant. Microsoft 
Excel was used for statistical calculations.
Histological assessment of colitis, NF-κB binding 
activity assay, ChIP assay, LPS injection and mouse model 
of endotoxin shock and shRNA knockdown and stable cell 
line generation. 
See Supplementary Materials and Methods section.
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